Allogene Therapeutics

ALLO · NASDAQ

$1.33+$0.03 (+2.31%)TodayMarket closed · Oct 20, 7:51 PM ET

Prev close $1.30

Latest news

NewsSep 14, 9:39 AM ETVandana Singh
Cellectis Pivots to Gene Editing in Major Overhaul
Press releaseAug 31, 8:30 AM ETGlobe Newswire
Allogene Therapeutics Announces Participation in September Investor Conference
Press releaseAug 12, 4:05 PM ETGlobe Newswire
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Press releaseAug 4, 8:30 AM ETGlobe Newswire
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
Press releaseJul 29, 8:30 AM ETGlobe Newswire
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
Press releaseJul 15, 8:30 AM ETGlobe Newswire
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
Press releaseMay 28, 5:02 PM ETGlobe Newswire
Allogene Therapeutics Announces Planned CEO Succession
Press releaseMay 26, 8:30 AM ETGlobe Newswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
NewsMay 13, 6:12 PM ET
Allogene Therapeutics Q1 2026 Earnings Call Transcript
Press releaseMay 13, 4:02 PM ETGlobe Newswire
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
NewsMay 13, 7:11 AM ET
Earnings Scheduled For May 13, 2026
Press releaseMay 6, 8:30 AM ETGlobe Newswire
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
NewsApr 15, 1:25 PM ETAvi Kapoor
Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings
NewsApr 14, 8:02 AM ETAvi Kapoor
JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
NewsApr 13, 12:59 PM ETVandana Singh
Allogene Therapeutics Stock Hits 52-Week High - Here's Why
NewsApr 13, 12:36 PM ETAvi Kapoor
Crude Oil Gains 5%; Fastenal Shares Fall After Q1 Earnings
Press releaseApr 13, 8:00 AM ETBusiness Wire
Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma
Press releaseApr 13, 7:30 AM ETGlobe Newswire
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Press releaseApr 10, 4:02 PM ETGlobe Newswire
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
NewsMar 26, 8:02 AM ETAvi Kapoor
Worthington Steel Posts Downbeat Earnings, Joins MillerKnoll And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
NewsMar 23, 1:05 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
Press releaseMar 12, 4:02 PM ETGlobe Newswire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
NewsMar 12, 7:11 AM ET
Earnings Scheduled For March 12, 2026
Press releaseMar 2, 8:30 AM ETGlobe Newswire
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
Press releaseFeb 5, 8:30 AM ETGlobe Newswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Press releaseJan 12, 10:14 AM ETGlobe Newswire
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
NewsDec 16, 1:09 PM ETVandana Singh
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday
Press releaseNov 10, 8:30 AM ETGlobe Newswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Press releaseNov 6, 4:05 PM ETGlobe Newswire
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
Press releaseOct 30, 8:30 AM ETGlobe Newswire
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
Press releaseAug 27, 8:30 AM ETGlobe Newswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
Press releaseAug 13, 4:05 PM ETGlobe Newswire
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
NewsAug 13, 4:32 AM ET
Earnings Scheduled For August 13, 2025
Press releaseAug 6, 8:30 AM ETGlobe Newswire
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
NewsAug 4, 7:47 AM ETAvi Kapoor
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday
Press releaseAug 1, 8:30 AM ETGlobe Newswire
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
NewsJul 25, 8:08 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseJul 23, 9:26 AM ETPRNewswire
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
Press releaseMay 23, 8:30 AM ETGlobe Newswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Cellectis Pivots to Gene Editing in Major Overhaul

Allogene Therapeutics Announces Participation in September Investor Conference

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

Allogene Therapeutics Announces Planned CEO Succession

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Allogene Therapeutics Q1 2026 Earnings Call Transcript

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

Earnings Scheduled For May 13, 2026

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings

JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Allogene Therapeutics Stock Hits 52-Week High - Here's Why

Crude Oil Gains 5%; Fastenal Shares Fall After Q1 Earnings

Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial in Large B-Cell Lymphoma

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

Worthington Steel Posts Downbeat Earnings, Joins MillerKnoll And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Earnings Scheduled For March 12, 2026

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Earnings Scheduled For November 6, 2025

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Earnings Scheduled For August 13, 2025

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

12 Health Care Stocks Moving In Friday's Pre-Market Session

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences